Abstract: Background: Lead inhibits the enzymes in the heme biosynthesis, mainly the δ-aminolevulinic acid dehydratase (ALAD) activities. The aims of this study was to establish ALAD activity assay in Taiwan and analyzed the effects of lead exposure on hematological system and the ALAD activity with the modification of the ALAD genotypes. Methods: Among 121 lead workers and 117 non-exposed workers, the data were from health examination. ALAD activity was determined by the standardized method of the European Community. ALAD genotyping was using a method of PCR-RFLP. For finding a threshold effect, we used generalized additive models (GAM) and scatter plots with smoothing curve, in addition to multiple regression methods. Results: There were 229 ALAD1-1 homozygotes, 9 ALAD1-2 heterozygotes were identified, and none of ALAD2-2 homozygote. Lead workers had significantly lower ALAD activity than non-exposed group (41.6 ± 22.1 vs. 63.3 ± 14.0 U/L, p-value < 0.001). The results of multiple regressions showed the blood lead level (BLL) was profound factor associated with ALAD activity inversely. The possible threshold of BLL affecting ALAD activity was around 10 μg/dL. Conclusions: ALAD activity was inhibited by blood lead, which could be a threshold of 10 ug/dL, which ALAD activity may be adopted as a biomarker of health examination for lead workers.
Introduction
Although the leaded gasoline had been phased out in year 2000 in Taiwan, lead continues to be a public health concern due to widely industrial uses. Workers exposed to lead with blood lead concentration in the range of 20-50 ug/dL were often reported. Chronic lead exposure had been associated with decreasing hemoglobin or anemia (1) . One of the mechanisms of lead induced anemia was, specifically, inhibition of heme synthesis. Lead inhibits three enzymes in the heme biosynthesis pathway-δ-aminolevulinic acid dehydratase (ALAD), coporphyrinogen oxidase, and ferrochelatasebut its effects on ALAD were the most profound. Lead inhibits ALAD stoichiometrically, and the degree of erythrocyte ALAD inhibition has been used clinically to gauge the degree of lead poisoning (2, 3) . ALAD inhibition results in the buildup of aminolevulinic acid, detectable in the plasma and urine. At the molecular level, lead displaces a zinc ion at the metal binding site, not the active site, producing inhibition through a change in the quaternary structure of the enzyme (4, 5) . Thus, the ALAD activity may be negative related to higher blood lead levels.
On the other hand, ALAD genotypes had reported as a modification of lead toxic effects. ALAD G177C polymorphism (ALAD 1-1, ALAD 1-2, and ALAD 2-2) was studied earliest (6) (7) (8) (9) . However, it was difficult to make a decision as to which genotype in fact the "at-risk" genotype, because the previous researched used different measures of outcome to indicate that each genotype was more susceptible to one or more adverse effects in comparison with the other (10, 11) . In addition to our knowledge, few studies to determine the ALAD activities in these different ALAD genotypes directly was also one of the reasons that difficultly make a decision as to which genotype was the "at-risk" genotype.
As a biomarker of lead exposure and availability, the value of measuring ALAD activity has not well established in Taiwan. The ALAD activity assay could and should be a diagnostic bioassay to evaluate both acute and chronic anemia induced by occupational and environmental exposure of lead and to differentiate it from the common anemia, such as malnutrition cause or hereditary causes. The determination of ALAD activity was well suited as a measure of lead-induced anemia. Meanwhile, few studies in occupational and environmental health determine the ALAD genotype in Taiwan. Hsieh et al (6) reported the ALAD genotypes in general population, which released most of the Taiwanese were ALAD 1-1 (95.4 %), and there was few ALAD 2-2. Studies using genetic markers of susceptibility to environmental and occupational lead toxicity raise the question of whether genes can make certain individuals more vulnerable to environmental and occupational lead. The latter was currently the most interesting question in the industrial and environmental health.
The goal of this study was to establish ALAD activity assay in Taiwan and analyzed the effects of lead exposure on hematological system and the ALAD activity with the modification of the ALAD genotypes.
Materials and Methods

Subjects
The study was carried out in a lead manufactory, where 121 workers have been followed up since 1990 with annual health examinations by our investigators (12) . We asked the workers whether they agreed to participating the study that checked their ALAD genotype and activity in addition to the regular health examination, and their consent form were obtained. On the other hand, age and sex matched 117 workers from the same area but different plants without lead used in their industries were selected to serve as control group; thus, their socioeconomic status was similar to the lead workers. Workers with renal or liver dysfunction, diabetes or pregnancy were excluded. The study protocol was approved by the institutional review board of Kaohsiung Medical University (IRB approval No. KMUH-IRB-950305), and informed consent was obtained from subjects before the study.
Health examination
Under the regulation of labor health protection in Taiwan, lead worker health examination should perform annually, which include physical examination, blood lead test, hematology test (including hemoglobin, hematocrit, complete blood counts), liver function test (Alanine Aminotransferase, ALT), renal function test (including serum creatinine, urine routine test). These examinations and tests were performed by our researchers and occupational physicians; meanwhile, blood and urine samples were frozen for analysis of genotypes and other tests in the central laboratory of our hospital. The body mass index (BMI) was measured their body weight and height, then calculated by weight (kilograms)/square of (height, meters).
Questionnaire
A short questionnaire on job title, medical and working history, family history, alcohol, and cigarette consumptions were administered in the health examination. 
ALAD genotyping
All (n=x238) genotyping were conducted by PCR amplification, followed by polymorphismspecific restriction enzyme digestion and gel analysis. ALAD genotyping was conducted by using the polymerase chain reaction and restricted fragment length polymorphisms (PCR-RFLP). Briefly, the initial amplification, using primer 50-AGACAGACATTAGCTCAGTA-30 and primer 50-GGCAAAGACCACGTCCATTC-30, generated a 916 bp fragment. The amplified fragment was cleaved by endonuclease MspI (6, 13).
ALAD activity
ALAD activity was measured using the European standardized method with spectrophotometric (UNICAM HEλIOSβ UV-VIS spectrometer, Thermo Spectronic, Cambridge, UK) determination carried out at 555 nm (14) . The principle of the method of the determination of ALAD activity was based on the incubation of the enzyme with excess δ-aminolevulinic acid. ALAD activity was measured by determining the amount of porphobilinogen formed under standard assay conditions. The porphobilinogen which was formed within a fixed time and mixed with modified Ehrlich's reagent, and the color developed was measured photometrically against a blank. The quantity of porphobilinogen produced was a measurement of the ALAD activity (15) .
The protocol used was adapted from the European Standardized Method of Berlin and Schaller (14) . The following reagents were prepared in advance: 1) buffers, 0.1 M Na2HPO4 and 0.1 M NaH2PO4, 2) 10 mM ALA in buffer, with the pH adjusted as required for the species being assayed, 3) 0.612 M trichloroacetic acid (TCA), and 4) modified Ehrlich's reagent: 2.5 g pdimethylaminobenzaldehyde was dissolved in 50 ml of glacial acetic acid in a perchloric acid hood; 24.5 ml of 70% perchloric acid was added and diluted to 100 ml with glacial acetic acid in a volumetric flask. For quality controls, all samples were measured triplication and the coefficients of variation (CVs) were less than 5% then accepted. The enzyme activity was expressed as units per liter (U/L) of erythrocytes (RBC) per minute and it was calculated according to the equation:
ALAD activity= (Abs×100×2×DF)/ (Htc×60×0.062)
where Abs= absorbance of sample, 2= (δ-ALAD conversion factor to porphobilinogen), DF= dilution factor (35 was used in the study), 60= incubation time (minute), and 0.062= coefficient (in liters per micromole × centimeter), and Htc= hematocrit (percent).
Statistical Analysis
To summarize data, descriptive statistics was used to calculate the means of continuous variables, including blood lead levels, age, working duration, and biochemistry data. For category variables, such as gender, smoking and alcohol consumption, job title, rates and proportions were used. Comparison of continuous variables between lead-exposed and non-exposed groups used independent t-test. However, because the ALAD 1-2 and 2-2 genotypes were rare, comparisons of continuous variables between genotypes, non-parametric method, such as Mann-Whitney U test, was used. Chi-square or Fisher's exact test were applied to comparison of category variables. Regression analysis could give us the association of ALAD activity and blood lead levels with adjustment of the other confounders. In addition, the effects of interaction between lead and ALAD activity or the other biochemical would be estimated by multiple regressions. Furthermore, we used generalized additive models (GAM) and scatter plots with smoothing curve to look at the curve shape of the relationship between ALAD activity and blood lead levels. The aim of these techniques was to look for a doseresponse curve and identify whether a threshold effect was present or not (16, 17) . Once a threshold was identified by visual inspection of the fitted curve, categorized blood lead levels to fit the multiple regression analysis was applied to the data. Significance was set at 0.05 (two-tailed). All statistical operations were performed on SAS version 9.3 and SPSS version 20. Table 1 showed the ALAD G177C gene polymorphism, characteristics and the measured parameters of the total 238 workers, There were 229 (96.2%) workers with ALAD type 1-1, 9 workers (3.8%) with ALAD type 1-2, and no one with ALAD 2-2 type was found in our study. Of all the measured parameters, there's no significant different between ALAD G177C genotypes: ALAD 1-1 and ALAD 1-2. The results of the comparison between the lead exposed group and non-exposed group showed in Table 2 . The proportion of male in the lead exposure group was significantly higher than those in the non-exposed group (81.0% and 61.1%, respectively) (p = 0.01), and there's no difference of the age, BMI, hemoglobin and blood glucose levels between the two groups. Average hematocrit (Hct) was slightly higher in the lead-exposed group than the non-exposed group, but no statistically significance was noted (p = 0.06). The proportion of smoking and drinking habits in the lead-exposed group were significantly higher than the non-exposed group. Means of blood lead concentrations were 19.7 and 2.9 ug/dL (p < 0.001) in the lead-exposed and non-exposed groups, respectively; meanwhile ALAD activity were 41.58 and 63.32 U/L (p < 0.001) in the lead-exposed and non-exposed groups respectively. No significantly different of the genotypes of ALAD G177C between these 2 groups. For the total 238 workers, a single linear regression was used to show the association between blood lead levels and ALAD enzyme activity. The correlation coefficient (r) was -0.760 (R 2 = 0.58, p < 0.001) (Figure 1, a) . Then we used generalized additive models (GAM) and scatter plot with smoothing curve to find a inflection point around 5 to 10 ug/dL of the blood lead levels. (Figure 1, b) . Figure 1 The association of blood lead concentrations (ug/dL) and δ-aminolevulinic acid dehydratase (ALAD) activity in all subjects (n=238). (a) Linear regression trend between ALAD activity and blood lead (R 2 = 0.58, p<0.001) found a dose-response relationship. (b) Generalized additive models (GAM) and scatter plots with smoothing (Loess, span: 70%) curve to look at the curve shape of the relationship between ALAD activity and blood lead levels find a inflection point around 5 to 10 ug/dL of the blood lead levels.
Results
We used multiple linear regression to analyzed 238 workers in our study. As shown in Table 3 , ALAD activity was significantly reduced by 1.04 U / L (P <0.001) for every 1 ug / dL of blood lead increased. The ALAD type (1-2 vs 1-1) did not make any significant difference. The variables of male, and drinking twice per-week were significantly decreased ALAD enzyme activity. Fasting blood glucose significantly inhibited ALAD enzyme activity, which each 1 mg / dL increasing in fasting blood glucose, the ALAD enzyme activity would decrease by 0.11 U / L (p <0.001). Age, BMI, and smoking habits had no significant effect on ALAD enzyme activity. For most Han (Chinese) people were ALAD 1-1 type, 96.2% workers in our study were also 1-1 type (n = 229). We excluded the workers with 1-2 type, then analyzed 229 workers who were ALAD 1-1 type by multiple linear regression analysis, which showed similar results (Table 3) . To further explored the effects of different blood lead concentrations on ALAD enzyme activity, 229 workers (excluding ALAD 1-2 type) were divided into 9 groups by categorized blood lead concentrations by 5 μg / dL intervals. Multiple linear regression analysis was used to adjust the influence factors such as age, sex, BMI, fasting glucose, smoking and drinking habits on the inhibition of ALAD enzyme activity. The changes of ALAD enzyme activity were compared with group 2 to 9 on the basis of the lowest mean blood lead concentration (blood lead <5, group 1). Results was shown in Table 4 , there was no significant difference in ALAD enzyme activity between group 2 and group 1. We could found while the concentration of blood lead reach group 3 (the blood lead range of 10.01 to 15.0 μg / dL, the activity of ALAD enzyme began to be significantly lower than group 1. In the other words, when the blood lead was less than 10 μg / dL, there would be no significant inhibition on ALAD enzyme activity, which could be a threshold level. When the blood lead concentration exceeds this threshold level, the inhibition of ALAD enzyme activity could be observed clearly. Table 4 Multiple linear regression analyses for the association with ALAD activity and blood lead in different lead levels (ALAD 1-1 type, n= 229).
Group
Range of blood lead (μg/dL) 
Discussion
In 1996, Sakai et al had the univariate linear regression of the ALAD enzyme activity and blood lead, from 191 male workers with blood lead concentrations ranging from 2.5 to 115.4 μg / dL. This result indicated a highly invert correlation between ALAD enzyme activity and blood lead concentration (18) . Our study had the similar result of the relationship between blood lead concentrations and ALAD enzyme. According to the analyses of GAM and multiple regressions, furthermore, a threshold around 10 ug/dL of blood lead level was suggested, which is easily to apply in the management of occupational health in the lead industry.
The results of our study showed that the average blood lead concentration exceeded 10 μg / dL would have a significant inhibition of the ALAD enzyme activity. Nordman et al also found that when the blood lead concentration exceeded 10 μg / dL, ALAD Enzyme activity exists a significant invert correlation (19) , which had the similar results to our study. However, according to the study of Wada et al., when the blood lead concentration reached about 15 μg / dL, ALAD enzyme activity was significantly inhibited by lead (20) , which was slightly higher than the results of our study. This might be the different method to measure of ALAD enzyme activity in their research. In 2003, Murata et al. used a benchmark dose method to study 186 lead workers with the concentration of blood lead between 2.1 to 62.9 μg / dL, found that workers with low blood lead levels (less than 10 μg / dL )had no significant effect on ALAD enzyme activity compared to the higher blood lead levels (21) . In 2017, a Mexican study reported a total of 633 pregnant women aged 13 to 43 years showed even lower LAD activity if blood lead levels between 2.2 and 10 ug / dL. One of the reasons might be pregnant condition that increased susceptibility to oxidative stress because of the mitochondria-rich placenta (22) . In our study, using the GAM with smoothing curve and multiple linear regression analysis of categorized blood lead levels to adjust the potential confounding factors, such as age, BMI, fasting blood glucose and smoking and drinking habits, we found that there was no significant inhibition of the ALAD enzyme activity if blood lead levels lower than 10 ug/dL. Thus, blood lead level 10 ug /dL would be a threshold of declining ALAD activity among common adults.
In the previous literature, Ratnaike et al. found the activity of ALAD was dependent on Schiff base formation between the substrate ALA and the amino group of a specific lysine residue of the enzyme. While this lysine residue were glycated by Schiff base formation with glucose, it would lead to loss of ALAD activity, which showed the blood glucose inhibits the activity of ALAD enzymes (23) . After adjustment of the other confounding factors, we also found the similar results in our study, which an increasing of 1 mg / dL fasting blood glucose, the ALAD enzyme activity would be reduced by 0.11 U / L (p <0.001).
It was also noted that smoking and drinking alcohol directly affected ALAD enzyme activity in the previous literature (24) , however, only the habit of drinking alcohol (twice per-week) was found a significant marginal effect on ALAD enzyme activity (p = 0.049) in our study. The first reason might be the measuring dose of smoking and drinking were not enough precisely, which was limited by the design of our study that evaluate the smoking and frequency of drinking by questionnaire. We could not quantify precisely.
According to the distribution of the ALAD G177C polymorphism in Taiwan population by Hsieh et al., the number of ALAD 1-1 phenotypes was 630 (95.4%), the number of ALAD 1-2 was 29 (4.4%), and only 1 of ALAD 2-2 (0.2%) (6). Yang et al. had the consistent distribution of ALAD variants of Han workers in southwestern China population (n=156), which the allele frequencies of ALAD1 and ALAD2 were 0.9679 and 0.0321, respectively (25) . Comparing the genotype distribution of ALAD G177C between our study and Hsieh et al., the results showed no significant difference (p = 0.222) while using chi-square test. Due to the extremely low proportion of ALAD2-2 genotypes in the Taiwanese population, we could not investigate the modified effect of ALAD G177C polymorphism on blood lead levels and ALAD enzyme activity.
Conclusions
The results of our study showed that ALAD enzyme activity is highly sensitive to lead inhibition and has a significant dose-related relationship with blood lead, which may be used as an indicator of lead exposure regulation. When the blood lead concentration exceeds 10 μg / dL, ALAD enzyme activity would have a significant inhibitory effect, and might be a threshold of limit value. Although both high blood sugar and lead both were associated to decline the ALAD activity, controlling blood sugar were important for workers themselves, industrial hygiene to control occupational lead exposure would be the most important issue in workplace.
